{"nctId":"NCT00551642","briefTitle":"Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies","startDateStruct":{"date":"2005-05-29","type":"ACTUAL"},"conditions":["Lung Disease"],"count":800,"armGroups":[{"label":"Inhaled Nitric Oxide (INO)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitric oxide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Nitric oxide","otherNames":["INO max®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inborn preterm infants 24+0 weeks-28+6 days weeks gestational age (defined by first trimester ultrasound or if not available based on the last menstrual period) who requires the use of surfactant within 24 hours of birth (either prophylactically, or for signs of developing respiratory distress), or who requires the use of continuous positive airway pressure (CPAP) (fraction of inspired oxygen concentration (FiO2) ≥ 0.30 on a mean airway pressure ≥ 4cm water (H2O)) within 24 hours of birth in order to maintain an oxygen saturation (SpO2) ≥ 85%.\n* Informed consent of the guardian.\n\nExclusion Criteria:\n\n* Outborn infants.\n* Infants ≥ 29 weeks gestational age.\n* Infants requiring FiO2 \\>0.5 to maintain SpO2 \\>85%, on a sufficient mean airway pressure (e.g., \\> 8 cm H2O on controlled mechanical ventilation (CMV)) in order to achieve adequate chest inflation (8-9 ribs on Chest X-ray) two hours after the proper administration of exogenous surfactant.\n* Any suspected congenital heart disease other than patent ductus arteriosus or atrial septal defect.\n* Any infant with severe bleeding or coagulation abnormalities at high-risk of diathesis, e.g., platelet \\<50,000 per millimeter cube (mm³), fibrinogen \\<0.5 gram per liter (g/L), other clotting factors \\<10%.\n* Any infant in whom a decision has been made not to provide full treatment, e.g., chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc.\n* Use of another investigational drug or device before or during the active study period.","healthyVolunteers":false,"sex":"ALL","maximumAge":"26 Hours","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress","description":"Survival without BPD is defined as the number of preterm infants of 36 weeks gestational age who survived the treatment period without the need for supplemental oxygen","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"262","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mortality at 7-year Follow-up","description":"Number of participants who died between 2 years and the 7-year Follow-up Period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Strengths and Difficulties Questionnaire Results for Participants at 7-year Follow-up","description":"The Strengths and Difficulties Questionnaire contained 25 questions that were used to create 5 scales (ranging from 10=most normal to 0=most abnormal) for emotional symptoms, conduct problems, hyperactivity, peer problems, and (10=most abnormal, 0=most normal) for prosocial.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"1.79"},{"groupId":"OG001","value":"2.1","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.55"},{"groupId":"OG001","value":"1.4","spread":"1.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"2.64"},{"groupId":"OG001","value":"3.4","spread":"2.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.41"},{"groupId":"OG001","value":"1.5","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"1.73"},{"groupId":"OG001","value":"8.4","spread":"1.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":170,"n":395},"commonTop":["Anaemia","Patent ductus arteriosus","Hyperbilirubinaemia","Jaundice","Hyperglycaemia"]}}}